| Year | Title | Author(s) |
| 2024 |
Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma
Cancer Medicine |
Seneviratne, JA Ravindrarajah, D Carter, DR Zhai, V Lalwani, A Krishan, S Balachandran, A Ng, E Pandher, R Wong, M Nero, TL Wang, SD Norris, MD Haber, M Liu, T Parker, MW Cheung, BB Marshall, GM |
| 2024 |
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis
Communications Biology |
Cheung, BB Mittra, R Murray, J Wang, Q Seneviratne, JA Raipuria, M Wong, IPL Restuccia, D Gifford, A Salib, A Sutton, S Huang, L Ferdowsi, PV Tsang, J Sekyere, E Mayoh, C Luo, L Brown, DL Stow, JL Zhu, SZ Young, RJ Solomon, BJ Chappaz, S Kile, B Kueh, A Herold, MJ Hilton, DJ Liu, T Norris, MD Haber, M Carter, DR Parker, MW Marshall, GM |
| 2021 |
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
Oncogene |
Cheung, BB Kleynhans, A Mittra, R Kim, PY Holien, JK Nagy, Z Ciampa, OC Seneviratne, JA Mayoh, C Raipuria, M Gadde, S Massudi, H Wong, IPL Tan, O Gong, A Suryano, A Diakiw, SM Liu, B Arndt, GM Liu, T Kumar, N Sangfelt, O Zhu, SZ Norris, MD Haber, M Carter, DR Parker, MW Marshall, GM |
| 2019 |
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Cancer Research |
Koach, J Holien, JK Massudi, H Carter, DR Ciampa, OC Herath, M Lim, T Seneviratne, JA Milazzo, G Murray, JE McCarroll, JA Liu, B Mayoh, C Keenan, B Stevenson, BW Gorman, MA Bell, JL Doughty, L Huttelmaier, S Oberthuer, A Fischer, M Gifford, AJ Liu, T Zhang, XL Zhu, SZ Gustafson, WC Haber, M Norris, MD Fletcher, JI Perini, G Parker, MW Cheung, BB Marshall, GM |